A novel therapy engineered by Northwestern Medicine investigators improved progression-free and overall survival for patients with newly diagnosed malignant gliomas, according to results from a recent phase I clinical trial published in The Lancet Oncology. In the study, investigators evaluated the safety of a novel therapy called NSC-CRAd-S-pk7 in patients newly diagnosed with malignant gliomas.